key: cord-0929310-vaksti8l authors: Fedson, David S.; Opal, Steven M.; Rordam, Ole Martin title: Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure” date: 2020-05-29 journal: mBio DOI: 10.1128/mbio.01243-20 sha: 62efa37b46940b8a86a51a938181c4cea6d4cc0c doc_id: 929310 cord_uid: vaksti8l nan W e thank Eftychios Siniorakis and colleagues for their thoughtful letter on how repurposing statins and angiotensin receptor blockers (ARBs) for coronavirus disease 2019 (COVID-19) treatment might affect patients with heart failure (1). Our understanding of the pathophysiology of COVID-19 disease has advanced rapidly in the past few months. The immunological dysregulation associated with the disease and the cardiovascular effects of infection (and especially the role of angiotensin converting enzyme 2 [ACE2]) have been comprehensively reviewed (2) (3) (4) (5) (6) (7) . Some patients who develop acute respiratory distress syndrome (ARDS) can be severely hypoxic and yet show relatively normal pulmonary compliance (8) . Endothelial dysfunction and intense inflammation seem to be important contributors to their distress (9) . In addition, pulmonary microvascular coagulopathy, sometimes associated with pulmonary or systemic embolization, has added a new dimension to clinical care (10) (11) (12) . Many physicians have added anticoagulation to their treatments (13) . Recently, van de Veerdonk and colleagues called attention to the contribution of the kallikrein-kinin system to COVID-19-induced ARDS (14, 15) . Although much attention has been focused on the relationship between the renin-angiotensin system (RAS) and COVID-19 (5-7), there is considerable cross talk between the RAS and kallikrein-kinin systems (14) (15) (16) . Experimentally, a reduction in ACE2 activity can impair inactivation of the B1 bradykinin receptor and this can be associated with an increase in inflammation-induced acute lung injury (17) . This is the backdrop for the concern raised by Siniorakis et al.: some COVID-19 patients might have heart failure and be receiving combination treatment with an angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI). Neprilysin is known to degrade bradykinin, and ARB treatment can increase bradykinin levels (18) . Thus, if bradykinin is involved in the genesis of the intense inflammation and microvascular coagulopathy seen in many COVID-19 patients (11, 14, 15) , the increase in bradykinin levels that accompanies ARB and neprilyin inhibitor treatment might be harmful. (Angiotensin converting enzyme inhibitors [ACEIs] also upregulate bradykinin, and they are more commonly associated with acute episodes of angioedema than are ARBs.) To our knowledge, there have been no reports of COVID-19 patients who were treated with both ARNIs and ARBs or ACEIs. We believe that physicians should consider combination statin/ARB treatment of severely ill COVID-19 patients (19) . Both drugs have beneficial effects on inflammation, coagulation abnormalities, and endothelial dysfunction. Recently published observational studies suggested that ACEIs, ARBs, and statins are associated with improved outcomes in COVID-19 patients (20, 21), although not all studies have shown this (22) . Whether ARNI treatment of COVID-19 patients would be harmful remains to be determined, although it has been shown to improve endothelial dysfunction in hypertensive rats (23) . The great advantage of ACEIs, ARBs, and statins is that they are widely available as inexpensive generics in resource-poor countries where lockdowns and social distancing would be difficult to implement. The same cannot be said for virtually all of the other COVID-19 treatments now being tested in clinical trials. COVID-19 interference with renin-angiotensin system in the context of heart failure Complex immune dysregulation in COVID-19 patients with severe respiratory failure Clinical and immunological features of severe and moderate coronavirus disease 2019 Immunology of COVID-19: current state of the science COVID-19, ACE2, and the cardiovascular consequences Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2 Understanding the renin-angiotensin-aldosterone-SARS-CoV-axis: a comprehensive review COVID-19 does not lead to a "typical" acute respiratory distress syndrome Endothelial cell infection and endotheliitis in COVID-19 The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease Immune mechanisms of pulmonary coagulopathy in COVID-19 pneumonia Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome Different cross-talk sites between the renin-angiotensin and the kallikrein-kinin systems Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg 9 bradykinin/ BKB1R axis and facilitates LPS-induced neutrophil infiltration Neprilysin inhibitors and bradykinin Hiding in plain sight: an approach to treating patients with severe COVID-19 infection Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19 posting date. Cardiovascular disease, drug therapy, and mortality in Covid-19 Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China Angiotensin II receptor-neprilysin inhibitor sacubitril/valsartan improves endothelial dysfunction in spontaneously hypertensive rats